Skip to main content

Livtencity Side Effects

Generic name: maribavir

Medically reviewed by Last updated on Oct 4, 2022.

Note: This document contains side effect information about maribavir. Some dosage forms listed on this page may not apply to the brand name Livtencity.

Applies to maribavir: oral tablet.

Serious side effects of Livtencity

Along with its needed effects, maribavir (the active ingredient contained in Livtencity) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Other side effects of Livtencity

Some side effects of maribavir may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

For Healthcare Professionals

Applies to maribavir: oral tablet.


The most common serious side effect reported in both treatment groups was in the infections/infestations system organ class (23% of patients in the group on this drug vs 13% in the group on investigator-assigned treatment [monotherapy or dual therapy with ganciclovir, valganciclovir, foscarnet, or cidofovir]) with CMV infection/disease being the most common in both groups. More patients in the investigator-assigned treatment group (32%) discontinued therapy due to a side effect compared to those in the group using this drug (13%); the most common side effects leading to discontinuation of this drug were dysgeusia, diarrhea, nausea, and recurrence of underlying disease.[Ref]

Nervous system

Taste disturbance was reported in 46% of patients using this drug; this resolved in 37% of patients during therapy (median duration: 43 days; range: 7 to 59 days) and rarely resulted in discontinuation of this drug. For patients with ongoing taste disturbances after stopping this drug, resolution occurred in 89%; the median duration of symptoms off therapy was 6 days (range: 2 to 85 days).[Ref]

Very common (10% or more): Taste disturbance (included ageusia, dysgeusia, hypogeusia, taste disorder; up to 46%)[Ref]


Increased creatinine greater than 1.5 to 2.5 mg/dL was reported in 33% of patients; increased creatinine greater than 2.5 mg/dL was reported in 7% of patients.[Ref]

Very common (10% or more): Increased creatinine (up to 33%)[Ref]


Very common (10% or more): Decreased hemoglobin (up to 32%), decreased platelets (up to 18%)

Common (1% to 10%): Decreased neutrophils[Ref]

Decreased hemoglobin (8 to less than 9.5 g/dL: 32%; 6.5 to less than 8 g/dL: 15%; less than 6.5 g/dL: 1%), platelets (50,000 to less than 100,000 cells/mcL: 18%; 25,000 to less than 50,000 cells/mcL: 12%; less than 25,000 cells/mcL: 5%), and neutrophils (750 to less than 1000 cells/mcL: 4%; 500 to less than 750 cells/mcL: 3%; less than 500 cells/mcL: 2%) have been reported.[Ref]


Very common (10% or more): Nausea (up to 21%), diarrhea (up to 19%), vomiting (up to 14%)[Ref]


Very common (10% or more): Fatigue (up to 12%)

Frequency not reported: CMV infection/disease, recurrence of underlying disease[Ref]


1. "Product Information. Livtencity (maribavir)." Takeda Pharmaceuticals America (2021):

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.